Macrophages in rheumatoid arthritis by Kinne, Raimund W et al.
Review
Macrophages in rheumatoid arthritis
Raimund W Kinne, Rolf Bräuer, Bruno Stuhlmüller*, Ernesta Palombo-Kinne
and Gerd-R Burmester*
Friedrich Schiller University, Jena, and *Humboldt University of Berlin, Berlin, Germany
Abstract
The abundance and activation of macrophages in the inflamed synovial membrane/pannus
significantly correlates with the severity of rheumatoid arthritis (RA). Although unlikely to be
the ‘initiators’ of RA (if not as antigen-presenting cells in early disease), macrophages
possess widespread pro-inflammatory, destructive, and remodeling capabilities that can
critically contribute to acute and chronic disease. Also, activation of the monocytic lineage is
not locally restricted, but extends to systemic parts of the mononuclear phagocyte system.
Thus, selective counteraction of macrophage activation remains as efficacious approach to
diminish local and systemic inflammation, as well as to prevent irreversible joint damage.
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AP = activator protein; BST = bone marrow stromal antigen; DMARD = disease-modifying antirheumatic drug; EBER(s) = Epstein-Barr
virus-encoded small nuclear RNA(s); GM-CSF = granulocyte–macrophage colony-stimulating factor; GRO = growth-related oncogene protein;
HLA = human leucocyte antigen; MCP = monocyte chemoattractant protein; MIP = macrophage inflammatory protein; NF-kB = nuclear factor-kB;
NO = nitric oxide; RA = rheumatoid arthritis; TGF = transforming growth factor; Th = T-helper (cell); TIMP = tissue inhibitor of metalloproteinase;
TNF = tumour necrosis factor.
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Introduction
Macrophages appear to play a pivotal role in RA because
they are numerous in the inflamed synovial membrane and at
the cartilage–pannus junction. They show clear signs of acti-
vation, such as overexpression of major histocompatibility
complex class II molecules, proinflammatory or regulatory
cytokines and growth factors [eg IL-1, IL-6, IL-10, IL-13,
IL-15, IL-18, tumour necrosis factor (TNF)-a and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF)],
chemokines and chemoattractants [eg IL-8, macrophage
inflammatory protein (MIP)-1 and monocyte chemoattractant
protein (MCP)-1], metalloproteinases and neopterin [1–4]. It
is unlikely that macrophages occupy a causal position in the
pathogenesis of RA (except for their function as antigen-pre-
senting cells in the hypothesis of a primary autoimmune dis-
order) [5]. However, these cells of the innate immune system
possess broad proinflammatory, destructive and remodelling
capacities, and considerably contribute to inflammation and
joint destruction both in the acute and chronic phases of RA.
Also, activation of the monocytic lineage is not restricted to
synovial macrophages, but extends to circulating monocytes
and other cells of the mononuclear phagocyte system,
including precursors of the myelomonocytic lineage in the
bone marrow [2,3,6].
Thus, even before the cause of RA is identified [whether it
is an infectious cause, or a clearly defined (auto)antigen or
a genetic alteration (or several)], several facts renderArthritis Research    Vol 2 No 3 Kinne et al
monocytes/macrophages attractive therapeutic targets.
The first is the correlation between radiological progression
of joint destruction and degree of synovial macrophage
infiltration [7]. Second, the coincidence of therapeutic effi-
cacy of conventional antirheumatic therapy with downregu-
lation of functions of the mononuclear phagocyte system
[8,9] is in accord with the increasing knowledge of
macrophage-specific effects of such drugs [10]. Third, the
efficacy of biological therapies directed at cytokines pro-
duced predominantly by macrophages has been demon-
strated [11,12]. Fourth, conventional or experimental drugs
can be targeted at macrophages, including their subcellular
compartments [2]. The final factor in support of targeting
monocytes/macrophages for treatment of RA is the differ-
ential activation of intracellular signal transduction path-
ways that underlie different macrophage effector functions,
in conjunction with the availability of more specific
inhibitors of key metabolic enzymes and/or particular signal
transduction pathways [13–15].
Differentiation of the mononuclear phagocyte
system in rheumatoid arthritis
Cells of the myelomonocytic lineage differentiate into
several cell types that are involved in disease (ie mono-
cytes/macrophages, osteoclasts and dendritic cells). As a
result of their marked plasticity, these differentiation path-
ways can be influenced by particular pathophysiological
stimuli (eg an excess/imbalance of cytokines or growth
factors), resulting in altered differentiation or maturation if
regulatory mechanisms fail. In RA, such alterations have
been already described at several levels (ie in inflamed
joints, peripheral blood and bone marrow).
In the RA synovial membrane, a first differentiation step is
that from recently immigrated monocytes to mature macro-
phages [16]. These subsets differentially colonise the syn-
ovial sublining and lining layer, respectively, as well as the
superficial and deep layers of the lining [7]. A possible
functional diversity in these areas, which is emphasized by
the expression of different activation markers and adhe-
sion molecules [17], may differentially contribute to
disease progression [7].
Locally, synovial macrophages also differentiate into stimu-
latory or inhibitory subpopulations, which are known to
influence T-cell reactivity differentially [18]. In experimental
arthritis, for example, immunoregulatory macrophages
greatly affect T-cell responses to arthritogenic proteins
[19] and, upon nonselective targeting, influence clinical
and histopathological improvement in arthritis [20]. In RA,
macrophage subpopulations may be responsible for the
separate synthesis of proinflammatory (eg IL-1 and TNF-a)
or regulatory cytokines (eg IL-10), the balance of which is
critical to perpetuation of disease [21,22]. A subset of
synovial macrophages may also exert a predominant role
in angiogenetic processes [23].
In the RA synovial fluid, a subset of mononuclear cells pre-
sents with a double phenotype of activated T cells and
macrophage-like cells [24]. Whether this promiscuity is
related to plasticity of common precursors, or is the
epiphenomenon of a central differentiation defect remains
to be clarified.
Alterations in the macrophage lineage are also evident in
extrasynovial compartments. In the bone marrow, RA
patients with active or severe disease display faster gener-
ation of CD14+ myelomonocytic cells and faster differentia-
tion into human leucocyte antigen (HLA)-DR+ cells than do
control individuals [25]. Myeloid precursors are also ele-
vated in the bone marrow adjacent to rheumatoid joints, in
correlation with the local levels of IL-1 [26]. A common
potential trigger for these bone marrow alterations may be
the altered monokine (eg IL-1, IL-6, TNF-a) or growth factor
milieu (eg GM-CSF), which builds up in the circulation
[6,8], and in the bone marrow [27] of RA patients. On the
other hand, the in vitro differentiation of bone marrow pre-
cursor cells becomes insensitive to GM-CSF [25], sug-
gesting intrinsic alterations in the myelomonocytic lineage.
Possible bone marrow anomalies may also underlie the
presence of highly proliferative potential colony-forming
cells in the peripheral blood of RA patients with severe
disease and high incidence of interstitial pulmonary
involvement [28,29], a factor of poor prognosis in RA.
Finally, bone marrow stromal cells also overexpress bone
marrow stromal antigen (BST)-1, a pre-B-cell growth
factor that is significantly elevated in the sera of patients
with severe RA [30], with growth inhibition effects on
monocytes/macrophages. These observations, as well as
that of the existence of a macrophage activation syndrome
in severe cases of systemic juvenile RA [31], suggest that
the spectrum of arthritis severity may be associated with
the degree of systemic activation of monocytes/
macrophages. This is also supported by the extra-articular
terminal differentiation of macrophages within rheumatoid
nodules, the latter a sign of clinical severity [32,33].
The involvement of the myelopoietic system in RA may
also partly explain the mode of action of slow-acting
antirheumatic drugs, possibly targeting altered precursors
[34], or that of stem-cell transplantation therapy [35].
Activation of the mononuclear phagocyte
system in rheumatoid arthritis
Synovial compartments
Synovial membrane
In the RA synovial membrane, a surface layer of HLA-DR+,
CD14+ and CD68+ macrophages is typically followed by
a layer of fibroblasts [2]. Below the lining layer,
macrophages are distributed in lymphoid aggregates or in
diffuse infiltrates, in the former case adjacent to activated
CD4+ lymphoid cells and in the latter case near CD8+http://arthritis-research.com/content/2/3/189
T cells [36], suggesting active participation in possible
(auto)immune processes. In addition, macrophages are
located close to synovial fibroblast-like cells that display
atypical morphology, which are believed to be centrally
involved in tissue destruction.
The degree of macrophage infiltration/activation correlates
not only with the joint pain and general inflammatory status
of the patient [37], but also with the radiological progres-
sion of permanent joint damage [7], the disease feature
that ultimately determines quality of life.
In chronic RA, the prevalence of certain histological config-
urations may represent an important variable for the clinical
course. High TNF-a and IL-1b production, for example, may
be associated with granulomatous synovitis, a rare condi-
tion that is more frequently associated with subcutaneous
rheumatoid nodules [32]. Conversely, these cytokines
appear to be modestly elevated in diffuse synovitis, which
may be associated with seronegative RA [32]. These fea-
tures may also explain some variability among studies on
the abundance of TNF-a and/or TNF-a receptor expression
in the RA synovial membrane [38,39], and, possibly, the
variable sensitivity to anti-TNF-a therapy [11].
Myeloid-related dendritic cells are also enriched in RA
synovial compartments. Their efficacy as antigen-present-
ing cells and their interdigitating location in perivascular
lymphoid aggregates are optimal prerequisites for the pre-
sentation of putative arthritogenic antigens to T cells and
for the regulation of B cells [40].
Cartilage–pannus and bone–pannus junction
At the site of tissue destruction, macrophages express sig-
nificant amounts of the inflammatory cytokines IL-1, TNF-a
and GM-CSF [2] and contribute to the production of the
proteases collagenase, stromelysin, gelatinase B and leuco-
cyte elastase [41]. Although gelatinase B levels positively
correlate with disease progression and severity [42], the
potential of macrophages to degrade cartilage matrix com-
ponents directly may be modest [41], assigning
macrophages the position of amplifyers of the pathogenetic
cascade (especially via activation of fibroblasts) rather than
primary effectors of tissue destruction. The situation may be
quite different at the bone–pannus junction, where osteo-
clasts derived from the myelomonocytic lineage strongly
contribute to bone erosion [43], possibly under the influ-
ence of local cell–cell contact and abundant cytokines.
Peripheral blood
The activation of circulating monocytes in RA, although
unclear in its extent [44], is evidenced by the following:
spontaneous production of prostanoids and prostaglandin
E2 [45], cytokines [8,46,47], soluble CD14 [2] and
neopterin [8], the latter a molecule exclusively produced
by human mononuclear phagocytes in correlation with
disease activity [48]; increased production of the matrix-
degrading enzyme gelatinase B [42,49] and the metallo-
protease inhibitor tissue inhibitor of metalloproteinase
(TIMP)-1 [50]; expression of manganese superoxide dis-
mutase, a critical enzyme for the control of oxygen radicals
[50]; increased phagocytic activity [51]; increased integrin
expression and monocyte adhesiveness [47,52]; pres-
ence of activated suppressor monocytes [18,53]; and,
more generally, gene activation with a pattern closely
resembling the synovial activation pattern.
Differential analysis of gene patterns in RA monocytes col-
lected upon initial and final therapeutic leukapheresis [6]
(a procedure that induces clinical remission in severe RA,
presumably by reducing the degree of monocyte activa-
tion) [8,54] has recently shed light on gene expression at
different stages of monocyte activation. In addition to the
expected cytokines (IL-1a, IL-1b, IL-6, TNF-a), gene acti-
vation in the florid stage of disease has also been docu-
mented for growth-related oncogene protein (GRO)-a/
melanoma growth-stimulatory activity, MIP-2/GRO-b, fer-
ritin, a1-antitrypsin, lysozyme, transaldolase, Epstein-Barr
virus encoded small nuclear RNA (EBER)-1/EBER-2-asso-
ciated protein, thrombospondin-1, an angiotensin
receptor-II carboxyl-terminal homologue, the RNA poly-
merase-II elongation factor, and for five unknown/function-
ally undefined genes [6]. Because a number of these
molecules (IL-1a, IL-1b, IL-6, TNF-a, GRO-a, ferritin,
lysozyme and thrombospondin-1) are also (over)expressed
in RA joints [6], monocytes appear to be preshaped in a
‘rheumatoid’ phenotype before their entry into the inflamed
synovial tissue. This is further supported by overexpres-
sion of the human cartilage glycoprotein gp39 [55], a late
macrophage differentiation marker [56], in circulating
monocytes and tissue macrophages. The findings regard-
ing novel or functionally undefined genes also indicate that
the extent of systemic monocyte/macrophage activation
remains to be fully explored.
Stimulation/regulation of monocyte/
macrophage activation in rheumatoid arthritis
Cell–cell interaction
A significant part of macrophage effector responses
occurs in the absence of soluble stimuli, through cell
contact-dependent signalling with several inflammatory
cells [57,58].
T cell–macrophage interaction
Accessory, inflammatory, effector and inhibitory macro-
phage functions can be stimulated by paraformaldehyde-
fixed T cells or plasma membranes of T cells [57],
provided that these are preactivated and express the
surface molecules that are involved in such stimulation (eg
CD69) [57]. In response to such interaction, monocytes
produce metalloproteinases, IL-1a and IL-1b [59,60].
Also, T cells that are prestimulated in an antigen-mimickingmanner stimulate TNF-a and IL-10 production, once they
are in contact with monocytes [61]. Conversely, fixed
T cells stimulated in an antigen-independent manner (ie
with IL-15, IL-2, or a combination of IL-6 and TNF-a)
induce monocyte production of TNF-a, but not IL-10 [62].
These findings have resulted in the hypothesis that early
RA reflects antigen-specific T cell–macrophage interac-
tions. Conversely, chronic RA may be associated with
antigen-independent interactions, which are dominated by
an exuberant cytokine milieu. This model would also
explain the relative paucity of IL-10 in the RA synovial
membrane (see below).
Fibroblast–macrophage interaction
Because macrophages and fibroblasts appear to be the
most active cells in the RA synovium, their interaction is
particularly interesting in view of the resulting inflammation
and tissue damage. Indeed, the mere contact of these
cells elicits the production of IL-6, GM-CSF and IL-8 [63].
The cytokine output can be enhanced or downregulated
not only by addition of proinflammatory or regulatory
cytokines (eg IL-4, IL-10, IL-13 or IL-1 receptor antago-
nist), but also by neutralization of the CD14 molecule [63].
Also,  in vitro model systems show significant cartilage
degradation by cocultures of mouse fibroblasts and
macrophages, a response markedly exceeding that
observed with each culture alone [64]. More recent
studies [65] have shown that purified human synovial
fibroblasts cocultured with myelomonocytic cell lines
induce cartilage degradation in vitro. The mechanism of
this response, however, seems to be paracrine- and not
cell contact-mediated, because cartilage degradation is
most effectively blocked by a mixture of anti-IL-1 and
anti-TNF-a monoclonal antibodies.
Soluble stimuli
Proinflammatory cytokines
IL-15, an IL-2-like cytokine with chemoattractant proper-
ties for memory T cells, is highly augmented in RA synovial
fluid, being produced by lining layer cells, including
macrophages [66]. Notably, IL-15-stimulated peripheral
blood or synovial T cells induce macrophages to produce
IL-1b, TNF-a, IL-8 and MCP-1 [62,67,68], but not IL-10
[61]. Because IL-15 is also produced by macrophages
themselves, this cytokine may (re)stimulate T cells, possi-
bly contributing to a self-perpetuating proinflammatory
loop [67].
The lymphokine IL-17, which is produced in approximately
90% of RA synovial explant cultures, but only in 16% of
osteoarthritis cultures, strongly stimulates macrophages to
produce IL-1 and TNF-a [69]. The induction of TNF-a pro-
duction can be completely reversed by addition of IL-10
[69]. IL-17, which is present in T cell-rich areas of RA syn-
ovial samples, is exclusively produced by T-helper (Th)0 or
Th1 clones that are derived from the synovial membrane
or synovial fluid of RA patients [70]. In addition, IL-17 indi-
rectly induces the formation of osteoclasts from progenitor
cells [71] and enhances the production of nitric oxide
(NO) in articular chondrocytes [72], thus potentially con-
tributing to cartilage and bone destruction.
In the RA synovial membrane IL-18, a cytokine of the IL-1
family [73], is expressed most prominently in CD68+
macrophages that are contained in lymphoid aggregates
[4]. CD14+ macrophages of the RA synovial fluid also
express the IL-18 receptor [4]. IL-18, either alone or in
concert with IL-12 and IL-15, strongly enhances the pro-
duction of IFN-g, TNF-a, GM-CSF and NO by cultured
synovial cells. Treatment with recombinant murine IL-18
markedly aggravates experimental arthritis [4], indicating
that IL-18 has proinflammatory effects in this disorder.
Bacterial/viral components
The ability of bacterial toxins or superantigens to initiate
proinflammatory responses that are characterized by
secretion of macrophage-derived cytokines is relevant in
view of the possible micro-organism aetiology of RA.
Lipopolysaccharide, for example, binds to macrophages
through the CD14 receptor and, in vitro, stimulates the
production of IL-1b, TNF-a and MIP-1a [74]. Staphylococ-
cal enterotoxin B, also a potent macrophage-activating
factor  in vitro and in vivo, enhances arthritis in MRL-lpr/lpr
mice. In this case, anti-TNF-a therapy reverses both the
severe wasting effects of staphylococcal enterotoxin B
and the incidence of arthritis, indicating that TNF-a is
central in this system [75]. Lipoarabinomannan, a
mycobacterial lipoglycan that is involved in attenuating
host immune responses and entry of mycobacteria into
macrophages [76], induces monocyte chemotaxis, as well
as selective production of IL-12 and subsequent differenti-
ation of T cells toward a Th1-like phenotype [77,78]. It
also stimulates macrophages to produce TNF-a,
GM-CSF, IL-1, IL-6, IL-8 and IL-10 [76].
More generally, the prolonged persistence of obligate or
facultative intracellular pathogens in macrophages may
directly lead to the development of arthritis. This is the
case with the Ross River virus, which causes human epi-
demic polyarthritis [79], or with the caprine-arthritis
encephalitis lentivirus, which causes a disorder in which
viral replication within macrophages correlates with the
severity of tissue pathology [80]. Further interesting cases
are arthritis associated with human immunodeficiency
virus-1 infection, which, as with all other manifestations of
this disease, is due to virus tropism for macrophages [81],
and that associated with human parvovirus B19 [82].
Hormones
RA undergoes clinical fluctuations during the menstrual
cycle and during pregnancy. These observations have a
pathophysiological basis in the expression of sex hormone
Arthritis Research    Vol 2 No 3 Kinne et alreceptors on RA synovial macrophages [83]. Indeed,
physiological concentrations of oestrogens stimulate the
production of the proinflammatory cytokine IL-1 by RA
macrophages. Conversely, higher oestrogen concentra-
tions inhibit IL-1 production, perhaps mimicking the clinical
improvement that occurs during pregnancy [83]. Thyroid
or other neuroendocrine hormones can also influence RA,
at least partly through actions on macrophages [84,85].
Regulation of monocyte/macrophage activation in
rheumatoid arthritis
Regulatory cytokines
The anti-inflammatory cytokine IL-4 is believed to play a
protective role in arthritis, although its virtual absence from
synovial samples points to the lack of protective mecha-
nisms, rather than to active regulation [86]. This Th2-like
cytokine downregulates monocyte/macrophage cytotoxic-
ity and cytokine production [87], including that of TNF-a
and TNF-a receptors [88], as well as IL-15-induced
chemokine production [68]. Notably, IL-4 decreases IL-1b
production while increasing IL-1 receptor antgonist pro-
duction, thus suggesting a ‘coordinated’ anti-inflammatory
approach [89]. IL-4 also decreases the mRNA production
of cyclo-oxygenase 2 and cytosolic phospholipase A2,
thereby reducing the levels of prostaglandin E2 [90,91]. In
RA, IL-4 decreases monokine production in ex vivo syn-
ovial specimens [86], or TNF-a receptor expression by
synovial fluid macrophages [88]. Importantly, IL-4 reduces
bone resorption [86] as well as synovial proliferation in
vitro [22]. Consistently, experimental therapy with IL-4
clearly suppresses streptococcal cell wall-induced arthri-
tis, a strongly macrophage-dependent model [89]. In
considering a combined antimacrophage and immuno-
therapeutic approach in autoimmunity, IL-4 should be the
elective molecule because of its ability to regulate
macrophages and to shift the cytokine pattern from a
Th1-like to a Th2-like predominance [92]; however, induc-
tion of fibrosis may limit its therapeutic applicability.
IL-10 is a macrophage-derived cytokine with clear autocrine
functions [93]. Accordingly, IL-10 reduces HLA-DR expres-
sion and antigen presentation in monocytes [87] and
inhibits the production of proinflammatory cytokines,
GM-CSF and Fcg receptors by synovial macrophages [87].
Consistently with cytokine and chemokine downregulation,
IL-10 clearly suppresses experimental arthritis [94].
In spite of IL-10 elevation in serum and synovial compart-
ments of RA patients [61,87], some studies [95] have
suggested a relative deficiency in IL-10. A combined
IL-4/IL-10 deficiency may therefore shift the cytokine
balance to a proinflammatory predominance. Because of
the autocrine effects of IL-10 [93], this may further
enhance the ‘rheumatoid’ macrophage imprint. Although
recombinant IL-10 appears to be an optimal candidate for
treatment of RA [96], the induction of soluble and mem-
brane TNF-a receptors on monocytes and synovial fluid
macrophages [88], as well as the lack of efficacy in some
cohorts of RA patients [97], currently question the broad
applicability of this treatment.
IL-11 is present in synovial membrane, synovial fluid and
sera of RA patients, and blockade of endogenous IL-11
increases endogenous TNF-a production in RA synovium
in vitro [98], whereas recombinant human IL-11 reduces
the production of TNF-a and IL-12 from activated
macrophages [99]. IL-11 may represent another example
of a paracrine regulatory loop, because IL-1a and TNF-a
synergistically stimulate the production of IL-11 in rheuma-
toid synovial fibroblasts [100]. Treatment with IL-11
decreases clinical severity and prevents joint damage in
murine collagen-induced arthritis [101], which is in accord
with high levels of IL-11 mRNA in clinically uninvolved
paws [102]. Clinical studies with recombinant human
IL-11 have been initiated in several inflammatory condi-
tions, including RA [103].
Similarly to IL-4 and IL-10, IL-13 exerts suppressive
effects in experimental arthritis, probably through a selec-
tive effect on monocytes/macrophages [104]. In RA, IL-13
is produced by synovial fluid mononuclear cells, which,
when exposed to exogenous IL-13, diminish their own pro-
duction of IL-1 and TNF-a [105].
The question regarding whether IL-16 is proinflammatory
or anti-inflammatory is still under debate [106]. In the RA
synovial membrane, IL-16 is present in CD68– synovial
fibroblasts [107] and CD8+ T cells [108]. In a human syn-
ovium/severe combined immunodeficiency mouse
chimera, IL-16 behaves as an anti-inflammatory cytokine
by strongly reducing levels of mRNA for IFN-g, IL-1b and
TNF-a [but not for transforming growth factor (TGF)-b],
and by decreasing the numbers of cells that express IFN-g
and TNF-a in the human implant [108]. IL-16 therefore
appears to be yet another potential candidate for RA treat-
ment, but one that requires care in view of its strong T-cell
chemoattractant features.
Monocyte/macrophage effector molecules in
rheumatoid arthritis
Proinflammatory cytokines
Tumour necrosis factor-a
TNF-a is a pleiotropic cytokine that increases the expres-
sion of cytokines, adhesion molecules, prostaglandin E2,
collagenase and collagen by synovial cells [109]. In RA,
TNF-a is mostly produced by macrophages in the synovial
membrane and at the cartilage–pannus junction [38] and
is believed to be a proximal cytokine in the inflammatory
cascade. While, on average, approximately 5% of synovial
cells express TNF-a mRNA in situ [110], the degree of
TNF-a expression in the synovial tissue appears to
depend on the prevailing histological configuration [32].
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mental and clinical observations: lymph node TNF-a pro-
duction precedes clinical synovitis in experimental
arthritides [111,112]; neutralization of TNF-a suppresses
collagen-induced arthritis and reduces inflammation in
human/murine severe combined immunodeficiency arthri-
tis [38,113]; TNF-a, in combination with IL-1, is a potent
inducer of synovitis [114]; transgenic, deregulated expres-
sion of TNF-a causes development of chronic arthritis
[115]; the TNF-a levels in the synovial fluid correlate with
the number of lining macrophages and with the degree of
radiologically assessed bone erosion [116]; and serum
TNF-a and soluble TNF receptors 1 and 2 are increased
in active, systemic juvenile rheumatoid arthritis, including
some cases of macrophage activation syndrome [31].
TNF-a exists as a membrane-bound and a soluble form.
Transmembrane TNF-a appears to be involved in local,
cell contact-mediated processes, and appears the prime
stimulator of the R75 receptor [117]. Interestingly, the
transgenic expression of this form alone is sufficient to
induce chronic arthritis [118]; likewise, a mutant mem-
brane TNF-a, which utilizes both R55 and R75 receptors,
can also cause arthritis [119]. Conversely, the soluble
form of TNF-a, shed via metalloprotease cleavage from the
membrane-bound form [120], primarily stimulates the R55
receptor, acting transiently and at a distance [117].
Tumour necrosis factor-a receptors
TNF-a receptors are found in synovial tissue and fluid of RA
patients [38,39,121], especially in severe disease [121].
There are two known TNF-a receptors: R55 (TNF-a receptor
1; high-affinity receptor) and R75 (TNF-a receptor 2; low-
affinity receptor). The resulting stable R55 or transient R75
character of the ligand–receptor complex mediates different
cellular responses to soluble and transmembrane TNF-a
[122]. In general, TNF-a receptors can operate indepen-
dently of one another, cooperatively, or by ‘passing’ TNF-a to
one another [117]. This complexity may explain the tremen-
dous sensitivity of target cells to minute concentrations of
TNF-a, as well as the considerable variety of its effects.
TNF-a receptors can also be shed, binding to soluble TNF-a
and hence acting as natural inhibitors in disease [123].
Consistent with the pivotal role of TNF-a in arthritis [124],
clinical trials with intravenous administration of chimaeric
anti-TNF-a monoclonal antibodies or TNF-a receptor con-
structs have shown remarkable efficacy in acute disease
[11], with long-term safety [125] and slowing-down of
radiological disease progression [126,127].
Also, in accordance with the activating role of TNF-a in
leucocyte extravasation [128], anti-TNF-a treatment
reduces endothelial E-selectin and vascular cell adhesion
molecule-1 in synovial samples, as well as the levels of
E-selectin, intercellular adhesion molecule-1, IL-8 and vas-
cular endothelial growth factor in the circulation [129].
This downregulartion may lead to deactivation of the vas-
cular endothelium and suppression of angiogenesis, as
substantiated in animal studies [129].
Interleukin 1
In RA, IL-1 gene expression is found predominantly in
CD14+ macrophages [130], and IL-1 levels in the synovial
fluid significantly correlate with joint inflammatory activity
[21]. This cytokine, which is believed to act in sequence
after TNF-a [38], appears to mediate most of the articular
damage in arthritis [21], because it induces proteoglycan
degradation and inhibition of proteoglycan synthesis
[131]. Also, IL-1 induces the production of the metallopro-
teases stromelysin and collagenase [21], and enhances
bone resorption [132]. In RA, the balance between IL-1
and its physiological inhibitor IL-1 receptor antagonist is
shifted in favour of IL-1, indicating a dysregulation that
may be crucial in promoting chronicity.
Chemokines
Several studies have documented the existence of a positive
feedback between the macrophage-derived TNF-a and IL-1
and chemotactic factors for monocytes, IL-8 and MCP-1
[133]. These factors are produced by synovial macrophages
in an autocrine manner [134]. The highest levels of secreted
IL-8 are observed in patients with seropositive RA, indicating
a correlation with a particularly vigorous macrophage activa-
tion [135]. Significantly, IL-8 derived from synovial macro-
phages is a powerful promoter of angiogenesis, thus
providing a link between macrophage activation and the
prominent neovascularization of the RA synovium [136].
Anti-inflammatory/regulatory cytokines
Macrophages also generate anti-inflammatory cytokines,
most notably IL-1 receptor antagonist and IL-10 (the latter
described under Regulatory cytokines, above), both
cytokines being engaged in autocrine regulatory loops.
Differentiated macrophages constitutively express IL-1
receptor antagonist, which binds to IL-1 receptors without
evoking physiological responses [21]. Significantly, this
protein is upregulated by proinflammatory cytokines,
including IL-1 itself or GM-CSF, inducing strong anti-
inflammatory effects [21]. By means of this feedback
mechanism, macrophages can therefore contribute to the
termination of inflammatory reactions. The critical rele-
vance of IL-1 in chronic RA [21], as well as the imbalance
between IL-1 and IL-1 receptor antagonist, constitute the
rationale for apparently successful therapy with IL-1
receptor antagonist [12,21,137].
Cytokines with a dual role in arthritis
Interleukin-6
IL-6 is the most strikingly elevated cytokine in RA, espe-
cially in the synovial fluid during acute disease [138]. The
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responses. However, although IL-6 levels in the synovial
fluid correlate with the degree of radiological joint
damage, and IL-6 and soluble IL-6 receptors promote the
generation of osteoclasts [139], this cytokine may also
protect cartilage in acute disease but promote excessive
bone formation in chronic disease [140]. Although IL-6 is
mostly produced by synovial fibroblasts and only partly by
macrophages [141], two findings suggest that the striking
IL-6 rise is a prominent outcome of macrophage activa-
tion: the morphological vicinity of IL-6-expressing fibro-
blasts with CD14+ macrophages in the RA synovial tissue
[141]; and the in vitro and coculture studies [63] that
showed that IL-1 stimulates IL-6 production.
Transforming growth factor-b
In RA, different forms of TGF-b and TGF-b receptors are
expressed by macrophages in the lining and sublining
[142], as well as at the cartilage–pannus junction [143]
and in the synovial fluid [144]. TGF-b is a main regulator of
connective tissue remodelling, controlling both matrix pro-
duction and degradation [145]. In experimental animals,
TGF-b can induce synovial inflammation, but can also sup-
press acute and chronic arthritis [144]. In the latter case,
TGF-b can act as a regulatory molecule, especially by
counteracting some of the effects of IL-1, including metal-
loprotease production [145] and phagocytosis of collagen
[146]. On the other hand, synovial fluid TGF-b induces the
expression of the FcgRIII macrophage receptor, the stimu-
lation of which induces release of tissue-damaging reac-
tive oxygen species [147]. The potential relevance of
FcgRs for the pathogenesis of arthritis has recently been
re-emphasized [148,149]. Likewise, TGF-b is a potent
chemotactic factor for leucocytes, promoting monocyte
adhesion and possibly resulting in excessive inflammatory
infiltration in chronic disease [150]. Another limit to the
therapeutic potential of TGF-b is the enhancement of syn-
ovial fibroblast proliferation [144].
The inhibiting effects of TGF-b on metalloproteases are
also controversial. While inhibition of gelatinase B and col-
lagenase suggest a protective role in tissue destruction
[151], the increase collagenase-3 in chondrocytes may
aggravate cartilage damage [152]. The effects of TGF-b
on TIMP are also ambiguous [153], because the regula-
tion of matrix metalloproteinase and TIMP may depend on
different tissue domains (superficial versus deep cartilage
layers) and may also vary for intracellular and extracellular
digestion of collagen [146,152]. Metalloproteases them-
selves can also affect TGF-b, by regulating the shedding
of latent TGF-b that is attached to decorin [154], and
thereby creating a loop that may enhance disease.
Nitric oxide and reactive oxygen species
In RA, variable numbers of synovial lining macrophages
may represent a source of NO [155,156]. Synovial cells
exposed to NO increase their TNF-a production [156],
possibly adding to the mechanisms that promote synovitis
[157]. NO may be relevant to arthritis also because of its
effects on bone remodelling [158]. However, NO can also
exert protective effects in experimental autoimmunity
[159], limiting perhaps the antiarthritic impact of selective
antagonists for human inducible NO synthase [160].
RA macrophages also produce reactive oxygen species
[161], which are involved in distal inflammatory processes.
Enhanced mitochondrial production of reactive oxygen
species in RA blood monocytes correlates with plasma
levels of TNF-a, confirming the stimulatory effect of this
cytokine on the production of reactive oxygen species [161].
In general, the link between macrophage activation and
molecules with dual activity (be they macrophage prod-
ucts or external stimuli, the latter being soluble, mem-
brane-bound, stimulatory, or suppressive factors) and the
number of different receptors that are involved in such
stimulation may result not only in potent proinflammatory
functions of macrophages, but also in powerful anti-inflam-
matory and tissue repair functions. Finally, macrophage
stimuli and macrophage responses rely heavily on
autocrine regulatory mechanisms, which makes it difficult
to discern the cause from the effect.
Lessons from experimental models of arthritis
Experimental arthritides with histological similarities to
human RA [2] have confirmed the role(s) of macrophages
and/or their products in synovitis [2], including the follow-
ing: macrophage infiltration and activation patterns; migra-
tion mechanisms of bone marrow-derived monocytes;
maturation into effector and immunoregulatory subpopula-
tions; activation of circulating monocytes and extra-articular
macrophages; leading role of TNF-a; sensitivity to cytokine-
based therapy, including gene therapy approaches; and
sensitivity to reduction of monocyte recruitment or deple-
tion of activated macrophages/osteoclasts.
In addition to the TNF-a transgenic models of arthritis, two
recent transgenic manipulations are worth mentioning.
The first, a back-cross of TNF-a transgenic mice with
arthritis-susceptible DBA/1 mice [162], results in arthritis
with enhanced production of TNF-a, IL-1 and IL-6 in the
synovial membrane, but with remarkable paucity of
macrophage and lymphocyte infiltration. The second, a
back-cross of a T-cell receptor transgene with the non-
obese diabetes (NOD) strain (K/B×N) [163], is charac-
terized by erosive arthritis with predominant macrophage
infiltration and other striking similarities to human RA: syn-
ovitis of the distal joints, lymphocyte clustering close to
macrophage infiltrates and predominant polymorphonu-
clear leucocyte exudation in the synovial fluid. Strikingly,
the autoantigen recognized by both T cells and B cells in
this model has recently been identified as the ubiquitous
http://arthritis-research.com/content/2/3/189glycolytic enzyme glucose-6-phosphate isomerase, len-
ding strong support to the concept that general breakage
of tolerance can lead to aggressive arthritis [164].
Treatment of human rheumatoid arthritis with
conventional antimacrophage approaches
The definition of the role of macrophage-derived cytokines
in the perpetuation of RA [2], of the pathophysiological and
therapeutic dichotomy between inflammation and cartilage
destruction, and of the crucial significance of activated
macrophages in the synovial membrane in relationship to
permanent joint damage [7] have prompted a radical re-
evaluation of the current regimens of anti-inflammatory and
disease-modifying treatments. In addition, research con-
cerning conventional agents with antimacrophage effects
is now aimed at potentiating such effects.
Disease-modifying antirheumatic therapy
Empirically introduced disease-modifying antirheumatic
drugs (DMARDs) possess a whole array of anti-
macrophage effects [10].
Gold compounds
Administration of gold compounds to RA patients results
in gold accumulation in the lysosomes of synovial
macrophages, especially in lysosome-rich sublining
macrophages [165]. In monocytes, gold compounds
inhibit Fc and C3 receptor expression, oxygen radical gen-
eration and IL-1 production [2]. Through their effects on
macrophages as accessory cells, gold compounds also
inhibit T-cell proliferation in response to antigen or
mitogen [2]. Gold compounds inhibit the production of
IL-1, IL-8 and MCP-1 [166] and decrease monocyte che-
motaxis in vitro [2]. In the synovial lining, this is paralleled
by a significant decrease in macrophage numbers and
IL-1, IL-6 and TNF-a production [9,10]. In vitro, gold salts
also inhibit angiogenic properties of macrophages, proba-
bly through their thiol moiety [167], which colocalizes in
macrophage lysosomes together with gold [165]. In
experimental arthritis, gold salts seem much more effective
as long-term disease-modifying drugs than as anti-inflam-
matory agents [168].
Methotrexate
One of the most effective DMARDs, methotrexate also
impairs chemotaxis of blood monocytes [2] and monokine
production [169], while increasing the production of cytokine
inhibitors, including soluble TNF-a receptor R75. Because
methotrexate shifts the IL-1/IL-1 receptor antagonist balance
in favour of IL-1 receptor antagonist, this drug may pharma-
cologically correct the imbalance between these two media-
tors [169]. A change in the monokine balance, including that
of TNF-a [169], may indirectly cause a selective decrease in
collagenase production in the synovial tissue. A surprising
caveat of methotrexate therapy, however, is the accelerated
formation of rheumatoid nodules in some patients [170].
Antimalarials
Antimalarials are endowed with significant antirheumatic
effects in early RA [171], but are apparently less effective
than gold. They are are attractive because of their limited
toxicity. Their tropism for lysosomes [172] is probably the
cause for their slow accumulation in macrophages, in
which they inhibit the release of arachidonate and the pro-
duction of prostaglandin E2 via phosholipase A2 inhibition
[173]. At high concentrations, antimalarials also inhibit the
production of IL-1 and TNF-a in lipopolysaccharide-stimu-
lated macrophages [174].
Corticosteroids
The potent anti-inflammatory effects of corticosteroids in
RA can be at least partly explained by transcriptional
downregulation of the inflammatory cytokines IL-1 and
IL-6, or, as recently reported, transcriptional and post-tran-
scriptional downregulation of TNF-a in monocytes [175].
Corticosteroids may also affect the balance of the func-
tionally distinct membrane-bound and soluble TNF-a
[117]. Interestingly, in vitro studies suggest that addition
of low doses of IL-4 and IL-10 decreases the dose of cor-
ticosteroids that is necessary to downregulate TNF-a,
possibly via a coordinated attack on activated
macrophages. Corticosteroid also decrease the produc-
tion of IL-8 and MCP-1 [134,166]; this, once optimally
exploited, may limit the self-perpetuating ingress of mono-
cytes into the inflamed joint.
Nonsteroidal anti-inflammatory drugs
Aspirin reduces the production of prostaglandin E2
through acetylation of the isoforms 1 and 2 of the cyclo-
oxygenase. Although its use is limited by the gastric side
effects (mostly dependent on cyclo-oxygenase-1 inhibi-
tion), there is a renewed interest in aspirin derivatives that
potently and selectively inactivate the inducible cyclo-oxy-
genase-2 isoform in isolated macrophages and in local
inflammation [15,176]. Cyclo-oxygenase-2-dependent
mechanisms selectively induce the production of IL-6
[177], the cytokine that is most highly increased in the RA
synovial fluid. Aspirin may affect macrophages also by
decreasing the TNF-a production via nuclear factor-kB
(NF-kB) mechanisms [178].
Experimental antimacrophage therapy
Counteraction of monocyte/macrophage activation at a
cellular level
Leukapheresis
In RA, repeated leukapheresis has proven effective in deplet-
ing the bloodstream of activated monocytes [8,54], leading
to reduced expression of differentiation markers, DR anti-
gens, cytokines, neopterin and prostaglandin E2 [6,8,54].
Apoptosis-inducing agents
A theoretical way of counteracting activated macrophages
or osteoclasts is to eliminate them physically from the
Arthritis Research    Vol 2 No 3 Kinne et alinflammatory foci, or from systemic loci that are relevant to
disease. Incorporation of liposome-encapsulated bisphos-
phonates by activated macrophages, for example, induces
apoptotic cell death in these cells [179], a process that
circumvents secondary tissue damage by restraining cellu-
lar organelles in apoptotic vesicles. Systemic application
to arthritic rats counteracts not only joint swelling, but also
joint destruction and subchondral bone damage [2,180].
The DMARD bucillamine also appears to display apoptotic
effects in monocyte lines [181]. Notably, liposome encap-
sulation can also be exploited for selective delivery of
macrophage-modulating drugs [2] and for gene therapy
constructs [182].
Control of gene transcription
The transcription of most cytokine genes in monocytes/
macrophages depends on the activation of NF-kB and
nuclear factor-kM transcription factors [183] or that of the
activator protein (AP)-1 complex. In RA synovial
macrophages, the expression of NF-kB is much more pro-
nounced than that of AP-1 [184], a selectivity that may
bear important therapeutic implications [185]. Accord-
ingly, the antiarthrtic effects of IL-4 may be based on the
selective suppression of NF-kB in macrophages [186].
IL-10 also downregulates the production of proinflamma-
tory monokines [187] (see above), inhibiting the nuclear
factors NF-kB, AP-1, or nuclear factor–IL-6 [188]. Unlike
IL-4, IL-10 can also enhance degradation of the mRNA for
IL-1 and TNF-a [189].
Vitamin D3
Vitamin D3 may exert major immunomodulatory effects in
RA [190] that are possibly based on the effects on acti-
vated synovial macrophages, resulting in positive regula-
tion of the anti-inflammatory cytokines IL-4 and TGF-b
[191]. Accordingly, dietary supplementation of vitamin D3
in collagen-induced arthritis suppresses or prevents arthri-
tis [192]. These immunomodulatory effects may directly or
indirectly underlie the observation that, in RA, the serum
levels of vitamin D3 are inversely correlated with parame-
ters of disease activity [193]. Vitamin D3 supplementation
may therefore represent a simple but effective therapy for
RA, although it may increase the risk of developing renal
concrements [194].
Gene therapy in arthritis
Gene therapy approaches have been applied to counteract
IL-1 and TNF-a, cytokines that are predominantly produced
by macrophages [182]. Gene therapy with IL-1 receptor
antagonist has proven efficacious in a number of experi-
mental arthritis models [182,195,196]. The same applies
to therapeutic overexpression of the soluble IL-1 type I
receptor–IgG and the type I soluble TNF-a receptor–IgG
fusion proteins, although the latter appears less effective
[182]. Recently, gene therapy approaches have also been
extended to anti-inflammatory cytokines (ie IL-4 [197],
IL-10 [182], IL-13 [104] and TGF-b [198]). An interesting
approach of gene therapy is to achieve ‘molecular synovec-
tomy’, either by expression of herpes simplex virus-thymi-
dine kinase, with subsequent administration of ganciclovir
[199,200], or by overexpression of Fas ligand, resulting in
synovial cell apoptosis [201,202]. Gene therapy aimed at
neutralizing proinflammatory macrophage products, overex-
pressing macrophage-regulating mediators, or simply elimi-
nating overly activated macrophages therefore carries
some promise for the treatment of arthritis [203].
Conclusion
Although it is unlikely that macrophages represent the ‘ini-
tiators’ of the pathogenetic cascade in RA, it is believed
that these cells act as amplifiers of local and systemic
inflammation, with a direct contribution to matrix degrada-
tion. Locally, macrophages are involved in recruitment and
activation of inflammatory cells, cell contact, or cytokine-
mediated activation/differentiation of neighbouring cells,
secretion of matrix-degrading enzymes, and neovascular-
ization. At a systemic level, macrophages amplify disease
via the acute phase response network, production of
TNF-a, development of bone marrow differentiation anom-
alies, and chronic activation of circulating monocytes.
Although identifying the diease aetiology remains the only
means to fully silence RA, efforts to therapeutically address
activated monocytes/macrophages have the advantage of
striking the very cell population that mediates/amplifies
most of the irreversible cartilage destruction, thus minimiz-
ing adverse effects on other cells that may have no (or mar-
ginal) effects on joint damage. The development of more
sophisticated means to reduce the numbers of activated
macrophages (eg by selective apoptosis-inducing agents),
to inhibit activation signals and/or their specific
macrophage receptors, or to selectively counteract the
macrophage products that act as disease amplifiers, raises
the hope of optimizing the therapeutic success against
joint inflammation and irreversible joint damage.
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